March 18 (Reuters) - Precigen Inc :
* PRECIGEN RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PRGN-2012 ADENOVERSE™ IMMUNOTHERAPY IN PATIENTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP)
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* PRECIGEN RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PRGN-2012 ADENOVERSE™ IMMUNOTHERAPY IN PATIENTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP)
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)